+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Influenza Medication Market - Global Forecast 2025-2030- Product Image
Influenza Medication Market - Global Forecast 2025-2030- Product Image
Sale

Influenza Medication Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888966
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The influenza medication market is undergoing swift transformation as drug makers and healthcare stakeholders adapt to new clinical standards, regulatory changes, and evolving patient needs. This report delivers senior leaders the insights required to make informed, strategic decisions within a complex, globally shifting landscape.

Market Snapshot: Influenza Medication Market Size and Growth Outlook

The Influenza Medication Market grew from USD 3.60 billion in 2024 to USD 3.79 billion in 2025. It is expected to continue growing at a CAGR of 5.04%, reaching USD 4.84 billion by 2030. These figures underscore healthy, sustained expansion driven by clinical innovation, responsive supply chains, and greater healthcare investment across major regions.

Scope & Segmentation: Comprehensive Market Breakdown

This analysis provides in-depth visibility into critical growth drivers, product pipelines, and investment opportunities across major segments and geographies:

  • Route of Administration: Inhalation, Intravenous, Oral including Suspension and Tablet forms.
  • Formulation Variants: Injection, Powder Inhaler, Suspension, Tablet (featuring Amantadine, Baloxavir Marboxil, Oseltamivir, Rimantadine).
  • Drug Classes: Endonuclease Inhibitors, M2 Ion Channel Inhibitors (Amantadine, Rimantadine), Neuraminidase Inhibitors (Oseltamivir, Peramivir, Zanamivir).
  • Distribution Channels: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy.
  • End User Profiles: Home Care, Hospitals, Outpatient Clinics.
  • Regional Analysis: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, UAE, Saudi Arabia, South Africa, and more), and Asia-Pacific (China, India, Japan, Australia, South Korea, and others).
  • Technological Innovations: Digital diagnostics, supply chain digitization, telehealth platforms, and adaptive clinical trial designs shaping drug development and delivery.
  • Company Coverage: Profiles and developments for leading companies including Hoffmann-La Roche AG, GlaxoSmithKline plc, CSL Seqirus Pty Ltd, Sanofi Pasteur SA, AstraZeneca plc, Shionogi & Co., Ltd, BioCryst Pharmaceuticals, Cipla Ltd, Teva Pharmaceutical Industries, and Sandoz International GmbH.

Key Takeaways for Senior Decision-Makers

  • Technological advancements such as rapid diagnostics and telehealth integration are redefining how therapies reach patients and accelerate intervention timings.
  • Collaborative models between drug developers, manufacturing networks, and clinical partners are vital for improving therapeutic outcomes and patient access.
  • Cross-sector partnerships and adaptive trial methodologies are expediting drug development and scaling up supply during routine and pandemic settings.
  • Regional strategies differ sharply, as market access relies on local policy, healthcare infrastructure, and regulatory harmonization.
  • Strategic company movements—including alliances, licensing, and portfolio optimization—are strengthening the market’s competitive landscape while responding to resistance trends and emerging needs.

Tariff Impact on Procurement and Supply Chains (2025)

  • Recent United States tariff adjustments have influenced procurement strategies, prompting some manufacturers to move steps of production domestically to reduce duties.
  • These tariff shifts require renegotiation of global supply agreements and can trigger capital and operational adjustments, emphasizing the need for resilient, diversified chains.
  • Ongoing bilateral negotiations around tariff exemptions are shaping competitive positioning and market entry options for manufacturers and suppliers.

Methodology & Data Sources

This report is grounded in a structured methodology combining primary interviews with clinical experts, regulatory authorities, manufacturing executives, and payers. Secondary research draws on peer-reviewed literature, regulatory documents, and clinical trial registries. Data triangulation and cross-validation ensure robust qualitative and quantitative findings for all presented trends.

Why This Report Matters

  • Guides C-suite and strategy leaders in identifying high-impact market trends and operational risks across global and regional portfolios.
  • Enables actionable decision-making on R&D priorities, geographic expansion, supply chain diversification, and partnership models to optimize growth.
  • Supports preparation for shifting regulatory and trade policy developments affecting pricing and access to influenza therapeutics worldwide.

Conclusion

This analysis delivers a strategic foundation for leaders navigating the rapidly changing influenza medication market. Aligning innovation, regulatory, and supply strategies is essential for maintaining competitive strength and ensuring patient access as the market evolves.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Adoption of mRNA platform technology for universal influenza vaccine development
5.2. Integration of digital health tools in influenza treatment adherence monitoring
5.3. Growth of over-the-counter antiviral medications combined with rapid home testing kits
5.4. Advances in monoclonal antibody therapies targeting influenza viral proteins among high-risk patients
5.5. Strategic partnerships between pharmaceutical companies and biotech startups for next-generation flu vaccines
5.6. Implementation of AI-driven forecasting models for selecting optimal seasonal influenza vaccine strains
5.7. Rising investment in targeted influenza prophylactics addressing pediatric and geriatric population needs
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Influenza Medication Market, by Route Of Administration
8.1. Introduction
8.2. Inhalation
8.3. Intravenous
8.4. Oral
8.4.1. Suspension
8.4.2. Tablet
9. Influenza Medication Market, by Form
9.1. Introduction
9.2. Injection
9.3. Powder Inhaler
9.4. Suspension
9.5. Tablet
9.5.1. Amantadine
9.5.2. Baloxavir Marboxil
9.5.3. Oseltamivir
9.5.4. Rimantadine
10. Influenza Medication Market, by Drug Class
10.1. Introduction
10.2. Endonuclease Inhibitors
10.3. M2 Ion Channel Inhibitors
10.3.1. Amantadine
10.3.2. Rimantadine
10.4. Neuraminidase Inhibitors
10.4.1. Oseltamivir
10.4.2. Peramivir
10.4.3. Zanamivir
11. Influenza Medication Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Influenza Medication Market, by End User
12.1. Introduction
12.2. Home Care
12.3. Hospitals
12.4. Outpatient Clinics
13. Americas Influenza Medication Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Influenza Medication Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Influenza Medication Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Hoffmann-La Roche AG
16.3.2. GlaxoSmithKline plc
16.3.3. CSL Seqirus Pty Ltd
16.3.4. Sanofi Pasteur SA
16.3.5. AstraZeneca plc
16.3.6. Shionogi & Co., Ltd
16.3.7. BioCryst Pharmaceuticals, Inc.
16.3.8. Cipla Ltd
16.3.9. Teva Pharmaceutical Industries Ltd
16.3.10. Sandoz International GmbH
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. INFLUENZA MEDICATION MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL INFLUENZA MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2024 VS 2030 (%)
FIGURE 8. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. INFLUENZA MEDICATION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. INFLUENZA MEDICATION MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. INFLUENZA MEDICATION MARKET: RESEARCHAI
FIGURE 26. INFLUENZA MEDICATION MARKET: RESEARCHSTATISTICS
FIGURE 27. INFLUENZA MEDICATION MARKET: RESEARCHCONTACTS
FIGURE 28. INFLUENZA MEDICATION MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. INFLUENZA MEDICATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL INFLUENZA MEDICATION MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL INFLUENZA MEDICATION MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY POWDER INHALER, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY POWDER INHALER, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY SUSPENSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR MARBOXIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR MARBOXIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ENDONUCLEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ENDONUCLEASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMANTADINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RIMANTADINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 121. CANADA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 122. CANADA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 123. CANADA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 124. CANADA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 125. CANADA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 126. CANADA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 127. CANADA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 128. CANADA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 129. CANADA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 130. CANADA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 131. CANADA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 132. CANADA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 133. CANADA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 134. CANADA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 135. CANADA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 136. CANADA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 137. CANADA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 138. CANADA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 139. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 140. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 141. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 142. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 143. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 144. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 145. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 146. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 147. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 148. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 149. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 150. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 151. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 152. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 153. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 232. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 233. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 234. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 235. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 236. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 237. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 238. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 239. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 240. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 241. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 242. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 243. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 244. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 245. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 248. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 249. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 250. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 251. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 252. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 253. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 254. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 255. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 256. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 257. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 258. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 259. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 260. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 261. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 262. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 263. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 283. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 284. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 285. ITALY INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 286. ITALY INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 287. ITALY INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 288. ITALY INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 289. ITALY INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 290. ITALY INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 291. ITALY INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 292. ITALY INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 293. ITALY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 294. ITALY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 295. ITALY INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 296. ITALY INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 297. ITALY INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 298. ITALY INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 299. ITALY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 300. ITALY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 301. ITALY INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 302. ITALY INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 303. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 304. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 305. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 306. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 307. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 308. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 309. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 310. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 311. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 312. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 313. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 314. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 315. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 316. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 317. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 318. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 319. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 320. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 324. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 325. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 326. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 327. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 328. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 329. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 330. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 331. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 332. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY M2 ION CHANNEL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 333. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2024 (USD MILLION)
TA

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Influenza Medication market report include:
  • Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • CSL Seqirus Pty Ltd
  • Sanofi Pasteur SA
  • AstraZeneca plc
  • Shionogi & Co., Ltd
  • BioCryst Pharmaceuticals, Inc.
  • Cipla Ltd
  • Teva Pharmaceutical Industries Ltd
  • Sandoz International GmbH

Table Information

Report AttributeDetails
No. of Pages189
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.79 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.84 Billion
Compound Annual Growth Rate5.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Influenza Medication - Global Strategic Business Report - Product Image

Influenza Medication - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Influenza Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Influenza Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 186 Pages
  • Global
From
Japan Influenza Medications Market, By Region, Competition, Forecast & Opportunities, 2020-2030F - Product Image

Japan Influenza Medications Market, By Region, Competition, Forecast & Opportunities, 2020-2030F

  • Report
  • 80 Pages
  • Japan
From
Antivirals Market Report 2025 - Product Image

Antivirals Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Antiviral Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Antiviral Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 135 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.